Dr. Joshua Richter, Mount Sinai Hospital, presents the results of pandemic’s influence on multiple myeloma management, treatment patterns, and provider contact with patients based from insights from the Connect® MM Registry.
Background:
The COVID-19 pandemic greatly impacted health care delivery systems throughout the United States (US). In-person clinical office visits were postponed or replaced by telehealth as a measure to reduce the spread of COVID-19 (Health and Human Services. ASPR TRACIE. 2021). The pandemic’s influence on multiple myeloma (MM) management, treatment patterns, and provider contact with patients has not yet been well studied. The Connect® MM Registry is a large, US, multicenter, prospective observational cohort study of patients with newly diagnosed MM. Real-world data (RWD) from the Connect MM Registry were evaluated to assess the impact of COVID-19 by examining baseline characteristics, treatment patterns, and the rates of clinical visits in both pre– and during–COVID-19 periods.
Conclusion:
The COVID-19 pandemic has had a substantial impact on the management of MM. RWE from the Connect MM Registry revealed that whereas treatment patterns were generally similar pre– and during–COVID-19, an increased uptake occurred in anti-CD38 agents, mainly daratumumab, in the latter time period. Whether this uptake was attributable to COVID-19 warrants further investigation. Overall, in the during–COVID-19 period, patients attended fewer in-person office visits, completed fewer disease assessments, and had fewer office/clinic/lab visits. Additionally, patients had more non–in-person office visits, which may have been due to the increased availability/adoption of telemedicine visits during the pandemic (Anderson et al. Digital Health. 2022). Collectively, these findings indicate that COVID-19 may have had an impact on patient treatment approach, affecting how frequently a patient was seen as well as the type of therapy they received. Additional follow-up will be needed to determine the long-term impact of COVID-19 on patients with MM.
ASH Abstract #3612: [ Ссылка ]
Authors:
Joshua Richter, MD, Sikander Ailawadhi, Hans C. Lee, MD, James W. Hardin, PhD, Howard R. Terebelo, DO, Rafat Abonour, MD, Lynne I. Wagner, PhD, Brian G.M. Durie, MD, James L. Omel, MD, Mohit Narang, MD, Kathleen Toomey, MD, Robert M. Rifkin, MD, Cristina J. Gasparetto, MD, Edward Yu, ScD, Jasmeet Anand, PharmD, Liang Liu, MS, Ying-Ming Jou, PhD and Sundar Jagannath
_______________
Improving Lives | Finding the Cure
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: [ Ссылка ]
Visit our website at: [ Ссылка ]
Find us online:
Facebook: @myeloma | [ Ссылка ]
Twitter: @IMFMyeloma | [ Ссылка ]
Instagram: @imfmyeloma | [ Ссылка ]
LinkedIn: [ Ссылка ]
Support the IMF | Donate Now! [ Ссылка ]
Category
Nonprofits & Activism
License
Standard YouTube License
In most cases, captions are autogenerated by YouTube.
